Categories

Catalog

Filter By

Availability

Availability

Brand

Brand

Weight

Weight

  • 0kg - 0.1kg

Used in/for

Used in/for

Release form

Release form

Intended for

Intended for

Подкатегории

Active filters

PURI NETHOL/25 pcs
€149.20
Faslodex 250 mg, 2 ready-made syringes
€1,261.00
Tagrisso 80 mg, 30 pcs
Tagrisso 40 mg, 30 pcs
ENDOXAN 1G, 6 pcs
€186.00
ENDOXAN 500MG, 6 pcs
ENDOXAN, 100 pcs
€89.20
Zevalin, 1.6 mg / ml
€18,850.00
Revlimid 5 mg/21pc
€4,166.00
Zometa ,4MG/100ML
€262.22
Firmagon 80MG, 1 pcs
Epirubicin 50, 1 pcs
Epirubicin 200, 1 pcs
€1,127.00
Epirubicin 10, 1 pcs
Etoposid 1000MG
€685.50
JANSSEN,Darzalex (Daratumumab) ,400 mg / 20ml, 1pcs
€2,637.70
JANSSEN,Darzalex (Daratumumab) ,100 mg / 5ml, 1pcs
LITAK, 2MG/ML  5 ML
€584.97
BCG Medac, 3 pcs
€727.00
BCG Medac, 1 pcs
€382.50
Temodal 100 mg, 20 pcs

Semisynthetic antitumor agent of plant origin, obtained by chemical synthesis from natural raw materials - European yew needles (Taxus baccata). White or almost white powder, highly lipophilic and practically insoluble in water. The molecular weight of 861.9.

Semisynthetic antitumor agent of plant origin, obtained by chemical synthesis from natural raw materials - European yew needles (Taxus baccata). White or almost white powder, highly lipophilic and practically insoluble in water. The molecular weight of 861.9.

The active substance is Mercapturin. It is capable of exerting both antitumor and immunosuppressive effects. It quickly penetrates into the tumor, thereby its further growth stops.

prescription

Manufacturer Aspen Germany GmbH Germany

€149.20
€1,261.00

The drug is a medicine that suppresses the effects of male sex hormone (testosterone) (non-steroidal antiandrogen).

Used to treat locally advanced prostate cancer and a high risk of disease progression.

The drug is a medicine that suppresses the effects of male sex hormone (testosterone) (non-steroidal antiandrogen).

Used to treat locally advanced prostate cancer and a high risk of disease progression.

€186.00
€89.20
Out of stock
€18,850.00

treatment of recurrent or refractory CD20-positive indolent B-cell non-Hodgkin lymphoma in adult patients;

consolidation therapy after achieving remission in previously untreated patients with follicular lymphoma.

The use of the substance Afatinib

Afatinib is indicated as monotherapy to patients who have not previously received tyrosine kinase inhibitors for the treatment of locally advanced or metastatic non-small cell lung cancer with a mutation (mutations) of the epidermal growth factor receptor

on prescription

Manufacturer Boehringer Ingelheim

€4,166.00

Kisplyx (Kisplyx) is indicated in combination with everolimus for the treatment of adult patients with renal cell carcinoma (PAC) after one previous vascular endothelial growth factor (VEGF) -targeted therapy.

Kisplyx (Kisplyx) is indicated in combination with everolimus for the treatment of adult patients with renal cell carcinoma (PAC) after one previous vascular endothelial growth factor (VEGF) -targeted therapy.

€262.22

The active substance in the drug is called zoledronic acid and is a representative of a group of substances called bisphosphonates. Zoledronic acid works by binding to bones and slowing down the speed of bone remodeling.

The specific antidote of paclitaxel is unknown. In case of an overdose of the drug Abraksan, symptomatic treatment and careful monitoring of the patient are carried out. Treatment should be directed to the main predictable complications (myelosuppression, mucositis, and peripheral neuropathy).

 

on prescription

Manufacturer Fresenius Kabi

Idelalisib (idelalisib) is used to treat relapsing chronic lymphocytic leukemia, relapsing follicular non-Hodgkin B-cell lymphoma, and small cell lymphocytic lymphoma. Sidelig is used in combination with rituximab (rituximab).

€1,127.00
€685.50
€2,637.70

1 ml of concentrate contains: active substance: daratumumab - 20 mg; excipients: glacial acetic acid - 0.186 mg, sodium acetate trihydrate - 2.967 mg, sodium chloride - 3.506 mg, mannitol - 25.500 mg, polysorbate-20 - 0.400 mg, water for injection - up to 1.0 ml

1 ml of concentrate contains: active substance: daratumumab - 20 mg; excipients: glacial acetic acid - 0.186 mg, sodium acetate trihydrate - 2.967 mg, sodium chloride - 3.506 mg, mannitol - 25.500 mg, polysorbate-20 - 0.400 mg, water for injection - up to 1.0 ml

The multicomponent composition regimens: osteogenic sarcoma, uterine sarcoma, lymphosarcoma, embryonal rhabdomyosarcoma, and pleural mesothelioma of the peritoneum, carcinoid tumors (including bronchogenic carcinoma, small cell lung cancer, thyroid cancer), pheochromocytoma, insulinoma, neuroblastoma, CNS tumor (glioma).

The multicomponent composition regimens: osteogenic sarcoma, uterine sarcoma, lymphosarcoma, embryonal rhabdomyosarcoma, and pleural mesothelioma of the peritoneum, carcinoid tumors (including bronchogenic carcinoma, small cell lung cancer, thyroid cancer), pheochromocytoma, insulinoma, neuroblastoma, CNS tumor (glioma).

€584.97

Litak is intended for the treatment of hairy cell leukemia. Litak solution is indicated as a second-line drug for the treatment of patients with recurrent or non-treatable lymphoproliferative diseases of low malignancy, such as follicular and diffuse non-Hodgkin's lymphoma, chronic lymphocytic leukemia, Valdenström macroglobulinemia.

The multicomponent composition regimens: osteogenic sarcoma, uterine sarcoma, lymphosarcoma, embryonal rhabdomyosarcoma, and pleural mesothelioma of the peritoneum, carcinoid tumors (including bronchogenic carcinoma, small cell lung cancer, thyroid cancer), pheochromocytoma, insulinoma, neuroblastoma, CNS tumor (glioma).

€727.00
€382.50